Read the latest ideas, insights and observations on the Australian Medicinal Cannabis Industry from the team at FreshLeaf Analytics.
Score check: Here’s how ASX pot stocks have responded to the US Senate result As ever, US politics is full of surprises — and ASX
From early 2021 you’ll technically be allowed to buy low-dose cannabis oil from pharmacies without a prescription. However, while the laws have been changed so
Therapeutic Goods Administration (TGA) makes final ruling on over-the-counter low-dose CBD, firing the starting gun for companies in race to bring products to market, increasing
Unregistered Cannabis Products Fail to Meet TGA Requirements 22nd September, 2020 The TGA’s recent Laboratories Testing Report on routine surveillance of unregistered products supplied to
Australia’s Most Comprehensive Medicinal Cannabis Report: Q3 2020 Thursday 17 September 2020 FreshLeaf Analytics is excited to release Australia’s most comprehensive medicinal cannabis Patient, Product
Green Fund: Australian Government Legalizes Over-The-Counter CBD
Cannabiz: Major doubts remain as industry reacts to CBD down scheduling
Stockhead Cannabis stocks were one of the rare groups in the green on a dismal day for the ASX on Wednesday following an interim ruling by the
FreshLeaf Analytics welcomes TGA interim decision on CBD down-scheduling September 9th 2020 Therapeutic Goods Administration (TGA) sticks to their guns on initial proposal for over-the-Counter
TGA Defers Decision to Pay for Epidyolex The Pharmaceutical Benefits Advisory Committee (PBAC), the body that decides whether Australians can have certain medicines subsidised by
July SASB numbers spike as Australia shoots for a more open minded future The Therapeutic Goods Administration (TGA) reported 5564 approvals this July for medicinal
TGA warns medical cannabis industry about advertising regulation breaches The Therapeutic Goods Administration (TGA), Australia’s health products regulator, has issued a stern warning to the
© 2021 All rights reserved, FreshLeaf Analytics
